Refine
Has Fulltext
- yes (26)
Is part of the Bibliography
- no (26)
Keywords
- COVID-19 (5)
- SARS-CoV-2 (3)
- Culture positive (2)
- De-isolation (2)
- Open pulmonary tuberculosis (2)
- Sputum smear-negative (2)
- TB-therapy (2)
- AIDS (1)
- Accelerators & Beams (1)
- Accelerators & storage rings (1)
- Antibody avidity (1)
- Antiretroviral therapy (1)
- Atomic & molecular beams (1)
- Atomic, Molecular & Optical (1)
- B.1.617.1 (1)
- B.1.617.2 (1)
- BNT2b2 (1)
- Beam loss (1)
- Charge-transfer collisions (1)
- Circular accelerators (1)
- Critical care (1)
- DST (1)
- Drug susceptibility testing (1)
- Ebola (1)
- Ebola virus (1)
- Electronic transitions (1)
- Epsilon (1)
- FFP3 respirator (1)
- Fingolimod (1)
- Forschung (1)
- Francisella tularensis (1)
- Francisella tularensis subspecies holarctica (1)
- GIIb/IIIa-receptor (1)
- HIV (1)
- HIV protease inhibitors (1)
- HNO (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Interstitial pneumonia (1)
- Kappa (1)
- Laborpersonal (1)
- Lehre (1)
- Low & intermediate-energy accelerators (1)
- Lung ultrasound (1)
- M. Intracellulare (1)
- M. avium (1)
- M. avium complex (1)
- M. chimaera (1)
- Multiple sclerosis (1)
- Mycobacteria (1)
- Mycobacterium avium complex (1)
- NTM (1)
- Non-tuberculous mycobacteria (1)
- Nontuberculous mycobacteria (1)
- Nuclear astrophysics (1)
- Nuclear physics of explosive environments (1)
- Nuclear reactions (1)
- ORL (1)
- Opportunistic infections (1)
- Otorhinolaryngology (1)
- PAC-1 (1)
- PAPR (1)
- Persistence SARS-CoV-2 antibodies (1)
- Personal protective equipment (1)
- Photon counting (1)
- Pneumocystis jirovecii (1)
- Pneumonia (1)
- Point of care (1)
- Powered air-purifying respirator (1)
- Protease inhibitor therapy (1)
- Radiative capture (1)
- Research (1)
- Residency (1)
- Respiratory infections (1)
- SARS-CoV‑2 pandemic (1)
- SARS-CoV‑2-Pandemie (1)
- Sensitivity (1)
- Sonography (1)
- Specialist training (1)
- Specificity (1)
- Teaching (1)
- Tularemia (1)
- University hospitals (1)
- Universitätskliniken (1)
- Viral infection (1)
- Weiterbildung (1)
- Zoonosis (1)
- arbeitsbedingte Infektionen (1)
- cardiac magnetic resonance (1)
- corona virus (1)
- delta (1)
- epitope mapping (1)
- healthcare personnel (1)
- healthcare worker (1)
- human sera (1)
- laboratory worker (1)
- leucocytes (1)
- mRNA1273 (1)
- medizinische Beschäftigte (1)
- medizinisches Personal (1)
- monoclonal antibodies (1)
- myocardial fibrosis (1)
- neutralization (1)
- neutralizing antibodies (1)
- occupational infections (1)
- platelets (1)
- recombinant vesicular stomatitis virus‐Zaire ebolavirus (1)
- scar (1)
- vaccination (1)
- x-ray techniques (1)
Institute
- Medizin (23)
- ELEMENTS (2)
- Physik (2)
- Biochemie, Chemie und Pharmazie (1)
The capacity of convalescent and vaccine-elicited sera and monoclonal antibodies (mAb) to neutralize SARS-CoV-2 variants is currently of high relevance to assess the protection against infections.
We performed a cell culture-based neutralization assay focusing on authentic SARS-CoV-2 variants B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.427/B.1.429 (Epsilon), all harboring the spike substitution L452R.
We found that authentic SARS-CoV-2 variants harboring L452R had reduced susceptibility to convalescent and vaccine-elicited sera and mAbs. Compared to B.1, Kappa and Delta showed a reduced neutralization by convalescent sera by a factor of 5.71 and 3.64, respectively, which constitutes a 2-fold greater reduction when compared to Epsilon. BNT2b2 and mRNA1273 vaccine-elicited sera were less effective against Kappa, Delta, and Epsilon compared to B.1. No difference was observed between Kappa and Delta towards vaccine-elicited sera, whereas convalescent sera were 1.6-fold less effective against Delta, respectively. Both B.1.617 variants Kappa (+E484Q) and Delta (+T478K) were less susceptible to either casirivimab or imdevimab.
In conclusion, in contrast to the parallel circulating Kappa variant, the neutralization efficiency of convalescent and vaccine-elicited sera against Delta was moderately reduced. Delta was resistant to imdevimab, which however, might be circumvented by a combination therapy with casirivimab together.
Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies
(2021)
Due to numerous mutations in the spike protein, the SARS-CoV-2 variant of concern Omicron (B.1.1.529) raises serious concerns since it may significantly limit the antibody-mediated neutralization and increase the risk of reinfections. While a rapid increase in the number of cases is being reported worldwide, until now there has been uncertainty about the efficacy of vaccinations and monoclonal antibodies. Our in vitro findings using authentic SARS-CoV-2 variants indicate that in contrast to the currently circulating Delta variant, the neutralization efficacy of vaccine-elicited sera against Omicron was severely reduced highlighting T-cell mediated immunity as essential barrier to prevent severe COVID-19. Since SARS-CoV-2 Omicron was resistant to casirivimab and imdevimab, genotyping of SARS-CoV-2 may be needed before initiating mAb treatment. Variant-specific vaccines and mAb agents may be required to treat COVID-19 due to Omicron and other emerging variants of concern.
Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies
(2021)
Due to numerous mutations in the spike protein, the SARS-CoV-2 variant of concern Omicron (B.1.1.529) raises serious concerns since it may significantly limit the antibody-mediated neutralization and increase the risk of reinfections. While a rapid increase in the number of cases is being reported worldwide, until now there has been uncertainty about the efficacy of vaccinations and monoclonal antibodies. Our in vitro findings using authentic SARS-CoV-2 variants indicate that in contrast to the currently circulating Delta variant, the neutralization efficacy of vaccine-elicited sera against Omicron was severely reduced highlighting T-cell mediated immunity as essential barrier to prevent severe COVID-19. Since SARS-CoV-2 Omicron was resistant to casirivimab and imdevimab, genotyping of SARS-CoV-2 may be needed before initiating mAb treatment. Variant-specific vaccines and mAb agents may be required to treat COVID-19 due to Omicron and other emerging variants of concern.
Objectives: To prospectively evaluate lung ultrasound in comparison with radiography and computed tomography (CT) for detecting HIV-related lung diseases.
Methods: Ultrasound examinations in HIV-positive patients were evaluated by three raters; available conventional imaging was evaluated by another rater. Results were compared with each other and the definite diagnosis. Interrater reliability was calculated for each finding.
Results: Eighty HIV-positive patients received lung ultrasound examinations; 74 received conventional imaging. The overall sensitivity was 97.5% for CT, 90.7% for ultrasound and 78.1% for radiography. The most common diagnoses were Pneumocystis jirovecii pneumonia (21 cases) and bacterial pneumonia (17 cases). The most frequent and sensitive ultrasonographic findings were interstitial abnormalities indicated by B-lines, independent of the aetiology. Interrater reliability was high for interstitial abnormalities (ICC=0.82). The interrater reliability for consolidations and effusion increased during the study (r=0.88 and r=0.37, respectively).
Conclusions: Ultrasound is a fast, reliable and sensitive point-of-care tool, particularly in detecting interstitial lung disease, which is common in HIV-associated illness. It does not effectively discriminate between different aetiologies. A longer learning period might be required to reliably identify consolidations and effusions.
Highlights
• Open pulmonary tuberculosis patient discharge policy was not reviewed for decades.
• After smear-negativity conversion, substantial cultural positivity may remain.
• It remains unclear, whether smear-negative patients still may be infective.
• The clinical relevance of this finding warrants further investigation.
Abstract
Objectives: Patients with open pulmonary tuberculosis (opTB) are subject to strict isolation rules. Sputum smear microscopy is used to determine infectivity, but sensitivity is lower than for culture. This study aimed to investigate the clinical relevance of this mismatch in contemporary settings.
Methods: Differential results between microscopy and culture were determined at the time of microscopic sputum conversion, from all patients with opTB between 01/2013 and 12/2017. In addition, data on HIV, multi/extensive drug-resistant TB status, time to smear- and cultural-negativity conversion were analyzed; and a Kaplan-Meier curve was developed.
Results: Of 118 patients with opTB, 58 had demographic data available for microbiological and clinical follow-up analysis; among these, 26 (44.8%) had still at least one positive culture result. Median time from opTB-treatment initiation to full microscopic sputum- or culture conversion, was 16.5 days (range 2-105), and 20 days (1-105), respectively (median difference: +3.5 days). Sixteen days after de-isolation, >90% had converted culturally. HIV- or multi/extensive drug-resistant TB status did not impact conversion time.
Conclusion: When patients with opTB were de-isolated after 3 negative sputum smear microscopy tests, a substantial part still revealed cultural growth of Mycobacterium tuberculosis complex, but it remains unclear, whether smear-negative and culturally-positive individuals on therapy are really infective. Thus, the clinical relevance of this finding warrants further investigation.
Objectives: Patients with open pulmonary tuberculosis (opTB) are subject to strict isolation rules. Sputum smear microscopy is used to determine infectivity, but sensitivity is lower than for culture. This study aimed to investigate the clinical relevance of this mismatch in contemporary settings.
Methods: Differential results between microscopy and culture were determined at the time of microscopic sputum conversion, from all patients with opTB between 01/2013 and 12/2017. In addition, data on HIV, multi/extensive drug-resistant TB status, time to smear- and cultural-negativity conversion were analyzed; and a Kaplan-Meier curve was developed.
Results: Of 118 patients with opTB, 58 had demographic data available for microbiological and clinical follow-up analysis; among these, 26 (44.8%) had still at least one positive culture result. Median time from opTB-treatment initiation to full microscopic sputum- or culture conversion, was 16.5 days (range 2-105), and 20 days (1-105), respectively (median difference: +3.5 days). Sixteen days after de-isolation, >90% had converted culturally. HIV- or multi/extensive drug-resistant TB status did not impact conversion time.
Conclusion: When patients with opTB were de-isolated after 3 negative sputum smear microscopy tests, a substantial part still revealed cultural growth of Mycobacterium tuberculosis complex, but it remains unclear, whether smear-negative and culturally-positive individuals on therapy are really infective. Thus, the clinical relevance of this finding warrants further investigation.